New data show cancer survival has reached a record high — nearly 70% of patients now live at least five years after diagnosis ...

Patients treated in an outpatient setting who later required admission spent an average of 12.1 days in the hospital, ...

The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...

Gibson, McNair Middle School's therapy dog, bid students farewell right before winter break. This week, he welcomed them back ...

BENGALURU: At a global cell therapy symposium in the city, oncologists said India offers CAR-T cell therapy at one-tenth the ...

Two months later, it increasingly seems that such discussion was a wasted effort, as the chance this ballroom will actually be built is rapidly disappearing. Perhaps it could have if Trump had ...

Please provide your email address to receive an email when new articles are posted on . ORLANDO — An in vivo chimeric antigen receptor T-cell therapy administered without lymphodepletion exhibited ...

MSK hematologist-oncologist Dr. Lia Palomba led a clinical trial that resulted in FDA approval of lisocabtagene maraleucel (Breyanzi®), a CAR T cell therapy, for marginal zone lymphoma. Marginal zone ...

Scientists at the University College London (UCL) have developed a novel therapy that helps treat patients with T cell acute lymphoblastic leukemia (T-ALL). This form of therapy used genome editing ...

Researchers at the Keck School of Medicine of University of Southern California (USC) have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response ...

A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved CAR-T cell therapies offers long-term survival and potential cures for adult ...